ArticleBMC ophthalmology2025
Scleral tunneling combined with the Tenon's capsule coverage in Glaucoma Drainage Valve surgery.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the clinical efficacy of an modified surgical technique using scleral tunneling and Tenon's capsule for implantation of the Ahmed Glaucoma Drainage Valve (AGV) in refractory glaucoma.
methodsThis research involved the retrospective collection of data from 78 patients diagnosed with refractory glaucoma who underwent implantation of the AGV using a modified technique combining scleral tunneling with autologous Tenon's capsule. The analysis focused on preoperative and 60-month postoperative indices, which included the surgical technique employed, intraocular pressure (IOP) measurements, the utilization of antiglaucoma medications, rates of surgical success, and the incidence of postoperative complications.
resultsThe findings suggest that the modified surgical technique exhibited an accuracy in the placement of implants. It also achieved remarkable postoperative control of IOP. The average IOP of the enrolled patients decreased from a preoperative maximum of 44.5 mmHg to 18.62 mmHg at 60 months postoperatively. Additionally, the usage of antiglaucoma medications decreased from an average of 2.88 preoperative medications to 1.76 medications at 60 months postoperatively. The rates of surgical success were recorded at 85.90% at 12 months, 82.54% at 24 months, 76.60% at 36 months, 71.88% at 48 months, and 66.67% at 60 months following the surgical procedure. It is noteworthy that no severe complications, including drain valve exposure and endophthalmitis, were reported.
conclusionsThe modified AGV implantation technique effectively regulated IOP, reduced medication dependence, and minimized severe complications. However, limitations such as small sample size and lack of a control group necessitate further large-scale trials to confirm its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.